CONTEXT: Although guideline-concordant depression treatment is clearly effective, treatment often falls short of evidence-based recommendations. Organized depression care programs significantly improve treatment quality, but employer purchasers have been slow to adopt these programs based on lack of evidence for cost-effectiveness from their perspective. OBJECTIVE: To evaluate the effects of a depression outreach-treatment program on workplace outcomes, a concern to employers. DESIGN, SETTING, AND PARTICIPANTS: A randomized controlled trial involving 604 employees covered by a managed behavioral health plan were identified in a 2-stage screening process as having significant depression. Patient treatment allocation was concealed and assessment of depression severity and work performance at months 6 and 12 was blinded. Employees with lifetime bipolar disorder, substance disorder, recent mental health specialty care, or suicidality were excluded. INTERVENTION: A telephonic outreach and care management program encouraged workers to enter outpatient treatment (psychotherapy and/or antidepressant medication), monitored treatment quality continuity, and attempted to improve treatment by giving recommendations to providers. Participants reluctant to enter treatment were offered a structured telephone cognitive behavioral psychotherapy. MAIN OUTCOME MEASURES: Depression severity (Quick Inventory of Depressive Symptomatology, QIDS) and work performance (World Health Organization Health and Productivity Questionnaire [HPQ], a validated self-report instrument assessing job retention, time missed from work, work performance, and critical workplace incidents). RESULTS: Combining data across 6- and 12-month assessments, the intervention group had significantly lower QIDS self-report scores (relative odds of recovery, 1.4; 95% confidence interval, 1.1-2.0; P = .009), significantly higher job retention (relative odds, 1.7; 95% confidence interval, 1.1-3.3; P = .02), and significantly more hours worked among the intervention (beta=2.0; P=.02; equivalent to an annualized effect of 2 weeks of work) than the usual care groups that were employed. CONCLUSIONS: A systematic program to identify depression and promote effective treatment significantly improves not only clinical outcomes but also workplace outcomes. The financial value of the latter to employers in terms of recovered hiring, training, and salary costs suggests that many employers would experience a positive return on investment from outreach and enhanced treatment of depressed workers. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00057590.
RCT Entities:
CONTEXT: Although guideline-concordant depression treatment is clearly effective, treatment often falls short of evidence-based recommendations. Organized depression care programs significantly improve treatment quality, but employer purchasers have been slow to adopt these programs based on lack of evidence for cost-effectiveness from their perspective. OBJECTIVE: To evaluate the effects of a depression outreach-treatment program on workplace outcomes, a concern to employers. DESIGN, SETTING, AND PARTICIPANTS: A randomized controlled trial involving 604 employees covered by a managed behavioral health plan were identified in a 2-stage screening process as having significant depression. Patient treatment allocation was concealed and assessment of depression severity and work performance at months 6 and 12 was blinded. Employees with lifetime bipolar disorder, substance disorder, recent mental health specialty care, or suicidality were excluded. INTERVENTION: A telephonic outreach and care management program encouraged workers to enter outpatient treatment (psychotherapy and/or antidepressant medication), monitored treatment quality continuity, and attempted to improve treatment by giving recommendations to providers. Participants reluctant to enter treatment were offered a structured telephone cognitive behavioral psychotherapy. MAIN OUTCOME MEASURES: Depression severity (Quick Inventory of Depressive Symptomatology, QIDS) and work performance (World Health Organization Health and Productivity Questionnaire [HPQ], a validated self-report instrument assessing job retention, time missed from work, work performance, and critical workplace incidents). RESULTS: Combining data across 6- and 12-month assessments, the intervention group had significantly lower QIDS self-report scores (relative odds of recovery, 1.4; 95% confidence interval, 1.1-2.0; P = .009), significantly higher job retention (relative odds, 1.7; 95% confidence interval, 1.1-3.3; P = .02), and significantly more hours worked among the intervention (beta=2.0; P=.02; equivalent to an annualized effect of 2 weeks of work) than the usual care groups that were employed. CONCLUSIONS: A systematic program to identify depression and promote effective treatment significantly improves not only clinical outcomes but also workplace outcomes. The financial value of the latter to employers in terms of recovered hiring, training, and salary costs suggests that many employers would experience a positive return on investment from outreach and enhanced treatment of depressed workers. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00057590.
Authors: M Von Korff; W Katon; T Bush; E H Lin; G E Simon; K Saunders; E Ludman; E Walker; J Unutzer Journal: Psychosom Med Date: 1998 Mar-Apr Impact factor: 4.312
Authors: Terry Bush; Carolyn Rutter; Greg Simon; Michael Von Korff; Wayne J Katon; Edward A Walker; Elizabeth Lin; Evette Ludman Journal: Int J Psychiatry Med Date: 2004 Impact factor: 1.210
Authors: E R Berndt; S N Finkelstein; P E Greenberg; R H Howland; A Keith; A J Rush; J Russell; M B Keller Journal: J Health Econ Date: 1998-10 Impact factor: 3.883
Authors: G E Simon; W Katon; C Rutter; M VonKorff; E Lin; P Robinson; T Bush; E A Walker; E Ludman; J Russo Journal: Psychol Med Date: 1998-05 Impact factor: 7.723
Authors: Andrea D Furlan; William H Gnam; Nancy Carnide; Emma Irvin; Benjamin C Amick; Kelly DeRango; Robert McMaster; Kimberley Cullen; Tesha Slack; Sandra Brouwer; Ute Bültmann Journal: J Occup Rehabil Date: 2012-09
Authors: Daphna Levinson; Matthew D Lakoma; Maria Petukhova; Michael Schoenbaum; Alan M Zaslavsky; Matthias Angermeyer; Guilherme Borges; Ronny Bruffaerts; Giovanni de Girolamo; Ron de Graaf; Oye Gureje; Josep Maria Haro; Chiyi Hu; Aimee N Karam; Norito Kawakami; Sing Lee; Jean-Pierre Lepine; Mark Oakley Browne; Michail Okoliyski; José Posada-Villa; Rajesh Sagar; Maria Carmen Viana; David R Williams; Ronald C Kessler Journal: Br J Psychiatry Date: 2010-08 Impact factor: 9.319
Authors: J Scott Ashwood; Bradley D Stein; Brian Briscombe; Lisa Sontag-Padilla; Michelle W Woodbridge; Elizabeth May; Rachana Seelam; M Audrey Burnam Journal: Rand Health Q Date: 2016-05-09
Authors: Debra Lerner; David A Adler; William H Rogers; Hong Chang; Annabel Greenhill; Elina Cymerman; Francisca Azocar Journal: Psychiatr Serv Date: 2015-03-01 Impact factor: 3.084
Authors: Michael F Hilton; Judith Sheridan; Catherine M Cleary; Harvey A Whiteford Journal: Int J Methods Psychiatr Res Date: 2009 Impact factor: 4.035